CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,740	$ 12,620
Marketable securities	43,224	14,529
Accounts receivable - related party	75	26
Prepaid and other current assets	2,368	781
Total current assets	54,407	27,956
Property and equipment, net	151	236
Operating lease right-of-use asset	1,177	1,149
Investment in Angel Pharmaceuticals	12,540	16,123
Other assets	632	89
Total assets	68,907	45,553
Current liabilities:
Accounts payable	2,582	1,525
Operating lease liability	185	1,374
Accrued and other liabilities	3,725	3,970
Warrant liability	28,910
Total current liabilities	35,402	6,869
Operating lease liability	937
Total liabilities	36,339	6,869
Stockholders' equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023	0	0
Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2024 and December 31, 2023; 67,899,779 and 49,038,582 shares issued and outstanding at December 31, 2024 and December 31, 2023	7	5
Additional paid-in capital	430,859	374,363
Accumulated other comprehensive loss	(1,288)	(967)
Accumulated deficit	(397,010)	(334,717)
Total stockholders' equity	32,568	38,684
Total liabilities and stockholders' equity	$ 68,907	$ 45,553